Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Pentec Health develops new Intradialytic Parenteral Nutrition solution

Pentec Health : 03 September, 2008  (New Product)
To address the specific nutritional needs of Chronic Kidney Disease (CKD) patients, Pentec Health has developed a new line of patent-pending Intradialytic Parenteral Nutrition (IDPN) solutions called Proplete.
IDPN is a type of IV nutrition administered through the dialysis machine directly into the bloodstream while patients receive dialysis. Proplete is formulated to address the protein malnourished dialysis population and has specific advantages for diabetes patients, as well as those with fluid management challenges.

The number of Chronic Kidney Disease (CKD) patients requiring haemodialysis, considered Stage 5 CKD, is growing every year in spite of medical advances.

This growth is fuelled by the ageing baby boomer population and the diabetes epidemic in the USA. There were nearly 100,000 new cases of Stage 5 CKD in 2005 alone, according to the United States Renal Data System, and approximately 600,000 in total today. That number is expected to climb 76 percent by 2020 and cost Medicare nearly $54 billion. (Refs 1, 2)

It is estimated that up to 70 percent of dialysis patients suffer from varying degrees of malnutrition that can result in unwanted weight loss and low blood protein levels, specifically, albumin (Ref 3). Low body mass index coupled with low serum albumin have been strongly linked to mortality and close to 60 percent of new dialysis patients begin therapy with albumin levels below the lower limit of normal (Ref 4, 5, 6). For dialysis patients who do not respond adequately to a standard approach, like liberalised diet and oral supplements, protein malnutrition and/or calorie malnutrition remain significant problems.

Eileen Moore, CNSD, RD, LD, a nationally recognised expert on IDPN, believes the new formulation may be of additional benefit to malnourished haemodialysis patients with diabetes. 'Traditional formulations for IDPN have been particularly troublesome for malnourished patients with diabetes. They often require close supervision of blood glucose and may require insulin administration. The unique formulation of Proplete provides an option for these patients and may make managing their glucose and fluids easier.'

'The introduction of Proplete reaffirms our commitment to patients, innovation and the renal nutrition market. Pentec Health has a 25 year history of offering traditional IDPN therapy and the introduction of Proplete allows us to extend the benefits to a broader range of patients,' said Joe Cosgrove, president and chief executive officer of Pentec Health. 'Given the current magnitude of diabetes, we are confident that Proplete will play a significant role in addressing unmet renal nutritional needs.'

Proplete is available exclusively from Pentec Health and can be ordered immediately to begin addressing the malnutrition needs of the haemodialysis population.

Ref 1 - United States Renal Data System. (2007). Incidence and Prevalence.
Retrieved Aug. 14, 2008 from

Ref 2 - Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, Collins A. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol. 2005 Dec;16(12): 3736-41.

Ref 3 - National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am. J Kidney Dis 2000; 35 (suppl 2):S1 -S140.

Ref 4 - Kalantar-Zadeh K, Kilpatrick R, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005;20:1880-1888.

Ref 5 - Beddhu S, Cheung A, Larive B, et al. Inflammation and Inverse Associations of Body Mass Index and Serum Creatinine With Mortality ion Hemodialysis Patients. J Ren Nutr 2007;17 (6): 372-380.

Ref 6 - United States Renal Data System. (2007). Patient Characteristics.
Retrieved Aug. 14, 2008 from

Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo